Ajanta Pharma Ltd announce Q4, FY19 results

Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported its performance for the 4th quarter & financial year ended 31st March 2019.

Q4 FY 2019 performance highlights (compared to Q4 FY 2018)

- Income from operations at Rs. 515 cr. against Rs. 530 cr.
- EBITDA at Rs. 127 cr. against Rs. 140 cr.; EBITDA at 25% of revenue.
- Profit after tax at Rs. 89 cr., against Rs. 94 cr.; PAT at 17% of revenue.

Year ended FY 2019 performance highlights (compared to FY 2018)

- Income from operations at Rs. 2,055 cr. against Rs. 2,131 cr.
- EBITDA at Rs. 566 cr. against Rs. 648 cr.; EBITDA at 28% of revenue.
- Profit after tax at Rs. 387 cr., against Rs. 469 cr.; PAT at 19% of revenue.

Commenting on the results, Mr. Yogesh Agrawal, Managing Director said: "The decline in anti-malarial business impacted the performance of the quarter and the year. Besides that, other business have posted the growths and continue to perform well. Our branded generic business in India and Emerging Markets continue to grow. Also US business posted healthy growth during the quarter and for the year."

Shares of AJANTA PHARMA LTD. was last trading in BSE at Rs.989.45 as compared to the previous close of Rs. 1028.5. The total number of shares traded during the day was 38659 in over 1337 trades.

The stock hit an intraday high of Rs. 1027.5 and intraday low of 978.65. The net turnover during the day was Rs. 38714428

Comments

Post a Comment

Popular posts from this blog

A morning walk down Dalal Street

Image
technically, the Nifty50 made a fresh record closing high but it reversed gains around 11,958 on that was similar to intraday high of 11,957 on May 27. The rupee May 28 declined by 18 paise to close at 69.69 against the US currency, weighed down by month-end dollar demand from importers and rising crude oil prices. On the institutional front, FPIs were net sellers in Indian markets for Rs 501 crore while DIIs were net buyers to the tune of Rs 269 crore, provisional data showed. Big News: On the earnings front, as many as 617 stocks will declare their results for the quarter ended March which include names like Aban Offshore, Adani Power, Bharat Electronics, Cadila Healthcare, Finolex Cables, GMR Infrastructure, Havells India, IDFC Ltd, IPCA Laboratories, Max India, NBCC etc. among others.   https://www.capitalaim.com/trading/stock-tips  
Read more

Nifty likely to show upmove towards 12,300-12,500 in the coming weeks

Image
Macro data will be in focus… GDP as well as Infrastructure output data for April is scheduled to come out post market hours later today Most experts feel that there is a high likelihood that the GDP growth could have slipped below 7 percent. A Reuters survey of economists forecast growth slipped to 6.3 percent annually in the three months ending in March, its slowest pace in six quarters. The central bank’s monetary policy committee (MPC), which has cut policy rates by 50 basis points this year, is expected to cut the repo rate by a further 25 basis points at its June 4-6 meeting, bringing it to 5.75%, the lowest since July 2010, added the Reuters report. https://www.capitalaim.com/trading/stock-tips
Read more